Please assess the completion status of the following clinical trial:

Trial Title: The Effect of Jincaopian Tablets on Chronic Pelvic Pain After Pelvic Inflammatory Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Meet the diagnostic criteria for chronic pelvic pain sequelae of pelvic inflammatory disease;~* The average VAS score of pain in the week before enrollment is ≥4;~* The McCormack scale of physical signs at the time of enrollment is 4 to 12 points (including 4 points and 12 points);~* Women aged 18 to 55 (including 18 and 55) with a history of sexual life;~* Voluntarily participate in this clinical trial, give informed consent and sign the informed consent form.~Exclusion Criteria:~* Pelvic inflammatory disease (acute attack);~* Pregnant or lactating women, women of childbearing age who are unwilling to take effective measures to prevent pregnancy during the trial and within 3 months after the trial;~* Critically ill or with surgical indications;~* Previously diagnosed with cervical intraepithelial neoplasia, primary/secondary dysmenorrhea, pelvic stasis syndrome and chronic pelvic pain caused by other non-pelvic inflammatory diseases;~* Complicated with specific vaginitis such as vulvovaginal candidiasis, trichomonas vaginitis, bacterial vaginosis, etc.;~* Gynecological tumors (maximum diameter of uterine fibroids greater than 3cm and submucosal fibroids), endometriosis, adenomyosis, acute cervicitis, tuberculous pelvic inflammatory disease, interstitial cystitis and other diseases related symptoms;~* Placement of intrauterine device in the past 3 months; absence of uterus and bilateral appendages;~* Received related treatment or took drugs with similar functions and indications within 14 days before the introduction;~* Have a history of allergy to the components of the test drug;~* Participated in other clinical trials within the past 3 months;~* The investigator believes that it is not suitable to participate in this clinical trial.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: f

Study Arms:
- Jincaopian Tablets high-dose group (Type: EXPERIMENTAL): Patients receive high dose Jincaopian Tablets 0.6g/day for 12 weeks.
- Jincaopian Tablets low-dose group (Type: EXPERIMENTAL): Patients receive low dose Jincaopian Tablets 0.3g/day for 12 weeks.
- Placebo group (Type: PLACEBO_COMPARATOR): Patients receive a matching placebo for 12 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).